The primary drivers for the decrease were lower corporate costs, employee-related costs due to the reduction in headcount, which occurred late in the first quarter of 2024, and lower spend for travel.

May 2, 2024 / receipt, needs a key / Joe Miller, CFO | earnings call 2024-05-02 | transcript 996e824d-0958-434a-b2be-224831828b5d | chars 11842-12042 | segment 11

The primary drivers for the increase in SG&A expense for the three months ended March 31, 2023, as compared to the same period ended March 31, 2022, were an increase in professional fees and services related to marketing and pharmacovigilance, non-cash shared-based compensation expense, and travel and related costs.

May 4, 2023 / receipt, needs a key / Peter Greenleaf, CEO | earnings call 2023-05-04 | transcript c27479a7-b761-4eda-b2fe-e4f3e147f616 | chars 15641-15958 | segment 15

The primary drivers for the increase for both periods were increased professional fees and services, mainly related to corporate legal matters and pharmacovigilance, an increase in travel costs in a COVID-endemic environment, as well as an increased participation in trade shows, medical conferences, and sponsorship to support the commercialization of Loop Kindness.

Feb 28, 2023 / receipt, needs a key / Joe Miller, CFO | earnings call 2023-02-28 | transcript 8e34a095-786c-4781-848a-e8198259649e | chars 17401-17768 | segment 17

The increase for the three months ended September 30th, 2022 was primarily due to an increase in professional fees related to corporate legal matters, an increase in travel costs now that COVID has normalized, and an increase in sponsorship and programs to support the commercialization of Loop Kindness.

Nov 3, 2022 / receipt, needs a key / Joe Miller, CFO | earnings call 2022-11-03 | transcript 0d9aa3bf-2dd0-451b-b7c6-e9e206c9869e | chars 18483-18787 | segment 18

Net Product Sales $305 million to $315 million (up 12% to 16%)

ir_statement / Sep 15, 2026 / receipt

Accelerate LUPKYNIS® commercialization by improving screening, diagnosis and treatment rates

ir_statement / Aug 30, 2026 / receipt

Continue LUPKYNIS commercial growth

ir_statement / Aug 30, 2026 / receipt

$305 million to $315 million

ir_statement / Aug 30, 2026 / receipt

$315 million to $325 million

ir_statement / Aug 30, 2026 / receipt

(up 11% to 15%)

ir_statement / Aug 30, 2026 / receipt

(up 12% to 16%)

ir_statement / Aug 30, 2026 / receipt

Following positive Phase 1 results, aritinercept advances toward clinical studies in two autoimmune diseases

ir_statement / Aug 30, 2026 / receipt

LUPKYNIS sales guidance for 2025 raised for second time this year, to $265 million to $270 million

ir_statement / Aug 30, 2026 / receipt

Third quarter 2025 LUPKYNIS sales experienced continued momentum following last year’s inclusion in American College of Rheumatology Guidelines, growing 27%

ir_statement / Aug 30, 2026 / receipt

$265 million to $270 million

ir_statement / Aug 30, 2026 / receipt

$275 million to $280 million

ir_statement / Aug 30, 2026 / receipt